UCB Group may be late to the party when it comes to innovative psoriasis biologics but the latest sets of skin clearance data presented on its investigational IL-17A and IL-17F inhibitor bimekizumab suggest that the Belgian group's therapy could prove to be superior to rivals, not least Novartis AG's big-earning Cosentyx.
The company has unveiled full data at the virtual American Academy of Dermatology meeting from the BE VIVID head-to-head study...